Pfizer begins clinical trial of vaccine for Ômicron
| Fact-checking | Autentic | DMCA | Report |
The study will look at how the modified vaccine should work in people who have not been vaccinated and in those who have received both doses and the booster.
Pfizer and BioNTech announced on Tuesday that they have started a clinical trial to test a new version of their vaccine, produced specifically to combat the new Omicron variant of COVID-19.
According to the companies, the trial will enroll up to 1,420 healthy adults between the ages of 18 and 55 and will assess whether the Ômicron vaccine is safe and generates a strong immune response.
The study will also look at how well the modified vaccine works in people who have not been vaccinated, as well as in people who have already had the two doses and the booster.
Counting on volunteers in the United States (USA), test participants will be divided into three groups: people vaccinated with the two doses of the vaccine, people fully vaccinated and with the booster dose and people not vaccinated.
“While current research and worldwide data show that boosters continue to provide a high level of protection against serious illness and hospitalization from Ômicron, we recognize the need to be prepared should that protection wane over time and potentially help address Ômicron and new variants in the future,” said Kathrin U. Jansen, Pfizer’s head of vaccine research and development.
How will the clinical trial work?
According to the company’s statement, the test was divided into three cohorts. The first group consists of people who received both doses of the current Pfizer-BioNTech vaccine between 90 and 180 days before enrollment. This group will receive one or two doses of the Ômicron-based immunizer.
Participants in the second group, who must have received three doses of the vaccine between 90 and 180 days before the start of testing, will receive one dose of the current immunizer or one based on Ômicron.
The third group will have people who have not taken any dose of any vaccine against COVID-19. Participants in this cohort will receive three doses of the vaccine based on the new variant.
“This study is part of our science-based approach to developing a variant-based vaccine that achieves a similar level of protection against Omicron as it did with previous variants, but with a longer duration of protection,” explains Professor Ugur Sahin, CEO and co-founder of BioNTech.
According to the statement, while the companies have previously announced that they expect to produce four billion doses of the vaccine by 2022, that capacity is unlikely to change if an adapted vaccine is needed.
know more
Omicron: Do current vaccines protect against the new variant?
Pfizer’s Third Dose Effective Against Omicron Variant
Why are coronavirus variants a concern?
Content for educational purposes only. Consult a Doctor.
The translator user relied on the following source:
Minha Vida Website – REF99827
Disclaimer – (English version>) This content has been prepared based on information from research, additional publications, or the translation/verification work of a volunteer editor of this web council. This is a non-profit service. It is strongly recommended that all details and information published be carefully verified. We never allow medication recommendations, medication package inserts or any medication guidance. We never allow partisan politics as information.
Isenção de responsabilidade – (versão em português): Este conteúdo foi preparado com base em informações de pesquisas, publicações adicionais ou no trabalho de tradução/verificação de um editor voluntário deste conselho web. Este é um serviço sem fins lucrativos. É altamente recomendável que todos os detalhes e informações publicadas sejam verificadas cuidadosamente. Nunca permitimos recomendações de medicamentos, bulas ou qualquer orientação sobre medicamentos. Nunca permitimos a política partidária como base para checagem. Para mais informações, leia nossos termos.
| Fact-checking | Autentic | DMCA | Report |
